Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03815916 · ClinicalTrials.gov registry record · Phase 2
31P-MRS Imaging to Assess the Effects of CNM-Au8 on Impaired Neuronal Redox State in Parkinson's Disease
A Phase 2 study, sponsored by Clene Nanomedicine.
- Completed
- Registry status
- Phase 2
- Development phase
- 13
- Enrollment target
NCT03815916 is a Phase 2 study that has completed, run by Clene Nanomedicine. The registered enrollment target is 13 participants.
The verdict
NCT03815916, a Phase 2 study, has completed, sponsored by Clene Nanomedicine.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 13 participants
- Enrollment target
Study Summary
REPAIR-PD is a single-center open label pilot, sequential group, investigator and patient blinded study to assess the CNS metabolic effects, safety, pharmacokinetics, and pharmacodynamics of CNM-Au8 in patients who have been diagnosed with Parkinson's Disease (PD) within three (3) years of Screening. The primary endpoint is the ratio of the oxidized to reduced form of nicotinamide adenine dinucleotide (NAD+:NADH) measured non-invasively by 31phosphorous magnetic resonance spectroscopy (31P-MRS).
Interventions
- DRUG Gold Nanocrystals
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2019-12-19 |
| Est. Completion | 2021-06-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03815916
The ClinicalTrials.gov registry entry for NCT03815916 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Clene Nanomedicine, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Gold Nanocrystals is the first listed.
NCT03815916 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03815916 about?
NCT03815916 is a clinical study titled "31P-MRS Imaging to Assess the Effects of CNM-Au8 on Impaired Neuronal Redox State in Parkinson's Disease". REPAIR-PD is a single-center open label pilot, sequential group, investigator and patient blinded study to assess the CNS metabolic effects, safety, pharmacokinetics, and pharmacodynamics of CNM-Au8 in patients who have been diagnosed with Parkinson's Disease (PD) within three (3) years of Screening...
What is the current status of trial NCT03815916?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 13 participants. The study started on 2019-12-19. Estimated completion is 2021-06-07.
What interventions are being tested in trial NCT03815916?
The interventions under investigation include: Gold Nanocrystals (DRUG).
Who is sponsoring clinical trial NCT03815916?
This trial is sponsored by Clene Nanomedicine, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.